Cancer Treatment Navigator
Helping to improve patient survival with emerging therapies

Medical Advisors

Benefits of Collaboration


If your cancer is particularly difficult to treat, Cancer Treatment Navigator may seek consultation with an Advisory Panel member. According to your geographic location and your individual cancer circumstances, Advisory Panel members or colleagues at their cancer centers might also be able to enroll you in a specific clinical trial that could offer promising treatment options.

The following list of physicians displays a selection of top experts in the field of medical oncology. These experts have agreed to be on the medical Advisory Panel and have supported Cancer Treatment Navigator since its inception.

Dr. C. Anthony Blau, MD

Dr. C. Anthony Blau is a Professor of Medicine at the Division of Hematology, University of Washington School of Medicine. He also serves as Co-Director, Stem and Progenitor Cell Biology Program, Fred Hutchinson Cancer Research Center & University of Washington Cancer Consortium. Dr. Blau graduated from Ohio State University. His work involves research into pluripotent stem cells, erythropoietin and cancer, genome architecture, and emerging genomic strategies for fighting cancer. Dr. Blau treats leukemia and blood disease patients in a hospital setting through the Seattle Cancer Care Alliance. He also serves as Co-Founder and President of Partners in Personal Oncology. This not-for-profit organization works toward breakthrough cancer treatments.

Dr. Brian J. Druker, MD

Dr. Brian J. Druker is the Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU) in Portland, OR. He is also the Associate Dean for Oncology of the OHSU School of Medicine, JELD-WEN chair of leukemia research, and an investigator of the Howard Hughes Medical Institute. He graduated from the University of California, San Diego School of Medicine. Dr. Druker was instrumental in getting the leukemia drug, Gleevec, onto the market and into the hands of patients with chronic mylogenous leukemia (CML). Dr. Druker has received numerous prestigious awards and accolades for his ground-breaking work. He was also elected to the Institute of Medicine of the National Academies, the American Association of Physicians, and the National Academy of Sciences. Dr. Druker’s current research focuses on understanding why some patients developing resistance to Gleevec and developing new, targeted treatments for other leukemias.

Dr. Douglas McNeel, MD, PhD

Dr. Douglas McNeel is an Associate Professor in Medicine in the Division of Hematology/Oncology at the Department of Medicine, University of Wisconsin in Madison, WI. Dr. McNeel received his Ph.D. in Biochemistry and Molecular Biology from the University of Chicago and received his M.D. from the University of Chicago, Pritzker School of Medicine. Dr. McNeel is an expert on prostate cancer, anti-tumor vaccines and other anti-cancer immunotherapies. Both his laboratory and clinical research has led to multiple publications in medical books and journals.

Dr. Bradley J. Monk, MD

Dr. Bradly J. Monk is a Professor and Director at the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology at the Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. Dr. Monk received his medical degree from the University of Arizona College of Medicine. His expertise involves the multidisciplinary prevention and treatment (surgery and chemotherapy) of vulvar, vaginal, cervical, uterine, fallopian tube, primary peritoneal and ovarian cancers. He is a recognized leader in developing new therapeutic approaches and has published over 120 peer review manuscripts.

Dr. Rainer Storb, MD

Dr. Rainer Storb is the Head of the Stem Cell Transplantation Biology Program at the Fred Hutchinson Cancer Research Center, Clinical Research Division, in Seattle, WA. He graduated from the University of Freiburg Medical School and moved to Seattle in 1965 were he participated in the birth of the bone marrow transplantation program. For the past 47 years, Dr. Storb has worked to develop new concepts in transplantation biology and apply them to patients. Many transplantation protocols currently in use have been directly extrapolated from his studies, his formulated drug schedule is now the “gold standard” in use at transplantation centers worldwide. Dr. Storb has won numerous awards for his work. For the past 18 years, Dr. Storb has been the 10th most cited physician/scientist and the 43rd most cited overall scientist worldwide per SCIENCE WATCH. During that time he has also been the second most quoted researcher in the field of Oncology.

Dr. Howard (Jack) West, MD

Dr. Howard (Jack) West is a Medical Oncologist at Swedish Hospital in Seattle, WA. He holds the position of Medical Director, Thoracic Oncology Program and Genitourinary Oncology Program at the Swedish Cancer Institute. In addition, Dr. West is an Affiliate Investigator at the Fred Hutchinson Cancer Research Center and an Acting Instructor at the Division of Medical Oncology, University of Washington, and the Seattle Cancer Care Alliance. Dr. West graduated from Harvard Medical School. His clinical research focuses on lung cancer, but he also maintains a significant interest in clinical research in genitourinary oncology. Dr. West has published numerous articles in the medical literature and has authored several book chapters.